Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia

• Published in: Translational psychiatry Vol. 10; no. 1; p. 158
• Main Authors: Tao, Ran, Li, Chao, Jaffe, Andrew E., Shin, Joo Heon, Deep-Soboslay, Amy, Yamin, Rae’e, Weinberger, Daniel R., Hyde, Thomas M., Kleinman, Joel E.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 19.05.2020; Nature Publishing Group
• Subjects: 38/22; 38/77; 38/90; 38/91; 45/61; 631/378/340; 692/699/476/1799; Adolescent; Behavioral Sciences; Biological Psychology; Brain; Cannabinoids; DNA Methylation; Hippocampus; Humans; Marijuana; Medicine; Medicine & Public Health; Mental disorders; Neurosciences; Pharmacotherapy; Polymorphism, Single Nucleotide; Prefrontal Cortex; Psychiatry; Psychosis; Receptor, Cannabinoid, CB1 - genetics; Receptors, Cannabinoid; Schizophrenia; Schizophrenia - genetics
• ISSN: 2158-3188; 2158-3188
• DOI: 10.1038/s41398-020-0832-8

Beyond being one the most widely used psychoactive drugs in the world, cannabis has been identified as an environmental risk factor for psychosis. Though the relationship between cannabis use and psychiatric disorders remains controversial, consistent association between early adolescent cannabis use and the subsequent risk of psychosis suggested adolescence may be a particularly vulnerable period. Previous findings on gene by environment interactions indicated that cannabis use may only increase the risk for psychosis in the subjects who have a specific genetic vulnerability. The type 1 cannabinoid receptor (CB1), encoded by the CNR1 gene, is a key component of the endocannabinoid system. As the primary endocannabinoid receptor in the brain, CB1 is the main molecular target of the endocannabinoid ligand, as well as tetrahydrocannabinol (THC), the principal psychoactive ingredient of cannabis. In this study, we have examined mRNA expression and DNA methylation of CNR1 in human prefrontal cortex (PFC), hippocampus, and caudate samples. The expression of CNR1 is higher in fetal PFC and hippocampus, then drops down dramatically after birth. The lifespan trajectory of CNR1 expression in the DLPFC differentially correlated with age by allelic variation at rs4680, a functional polymorphism in the COMT gene. Compared with COMT methionine 158 carriers, Caucasian carriers of the COMT valine 158 allele have a stronger negative correlation between the expression of CNR1 in DLPFC and age. In contrast, the methylation level of cg02498983, which is negatively correlated with the expression of CNR1 in PFC, showed the strongest positive correlation with age in PFC of Caucasian carriers of COMT valine 158 . Additionally, we have observed decreased mRNA expression of CNR1 in the DLPFC of patients with schizophrenia. Further analysis revealed a positive eQTL SNP, rs806368, which predicted the expression of a novel transcript of CNR1 in human DLPFC, hippocampus and caudate. This SNP has been associated with addiction and other psychiatric disorders. THC or ethanol are each significantly associated with dysregulated expression of CNR1 in the PFC of patients with affective disorder, and the expression of CNR1 is significantly upregulated in the PFC of schizophrenia patients who completed suicide. Our results support previous studies that have implicated the endocannabinoid system in the pathology of schizophrenia and provided additional insight into the mechanism of increasing risk for schizophrenia in the adolescent cannabis users.